AFFILIATIONS
1 St Vincent's Health Melbourne, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
2 Monash University, Melbourne, Victoria, Australia
3 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
4 The Alfred Hospital, Melbourne, Victoria, Australia
5 Monash University, Melbourne, Victoria, Australia
6 The University of Melbourne, Melbourne, Victoria, Australia
7 St Vincent's Health Melbourne, Melbourne, Victoria, Australia
8 Monash University, Melbourne, Victoria, Australia
9 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
10 Nepean Cancer Care Centre, Sydney, New South Wales, Australia
11 Austin Health, Melbourne, Victoria, Australia
12 Concord Repatriation General Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
13 Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
14 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
15 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
16 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
17 Monash University, Melbourne, Victoria, Australia, The Alfred Hospital, Melbourne, Victoria, Australia
18 St Vincent's Health Melbourne, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
19 St Vincent's Health Melbourne, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
ABSTRACT
Introduction:
Proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (anti-CD38) are fundamental to the treatment of multiple myeloma (MM). Recently, therapies targeting the B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5d) have substantially improved outcomes for triple-class (PI, IMiD, anti-CD38) exposed patients. Nonetheless, late line curative therapies are elusive and patients who progress following penta-class exposure (PI, IMiD, anti-CD38, BCMA, GPRC5d) represent a highly refractory, and understudied population with limited treatment options. We aimed to evaluate the Australian real-world experience to estimate and compare the overall survival (OS) and progression-free survival (PFS) for triple-, quad- (PI, IMiD, anti-CD38, BCMA), and penta-class exposed MM patients through the Australian Myeloma and Related Diseases Registry (MRDR).
Methods:
Among 6885 MM patients registered on the MRDR – a national myeloma registry in Australia – who were diagnosed between 2012 and 2026, we identified cohorts with International Myeloma Working Group (IMWG)-defined disease progression following triple- (n=487), quad- (n=48), or penta-class (n=16) therapy. OS and PFS for each cohort were estimated by the Kaplan–Meier method. For OS and PFS, the index date was the date of progression following triple-, quad-, or penta-class exposure.
Results:
Among triple-, quad- and penta-class exposed cohorts, baseline characteristics included: median age at diagnosis 67, 61, 62 years; 62%, 73% and 56% male; and the median number of prior lines of therapy was 4, 6 and 7. With regards to cytogenetics, del(17p) was identified in 8.8%, 4.0% and 6.3%, and R-ISS stage was III at diagnosis in 30.5%, 33% and 13.3% of patients, respectively. In the triple-class exposed cohort, the median OS was 16.7 months (95% CI, 13.8–21.2) and median PFS was 6.1 months (95% CI, 4.8–7.3). In the quad-class exposed cohort, the median OS was 10.4 months (95% CI, 6.1–23.9) and median PFS was 3.6 months (95% CI, 2.1–5.3). The penta-class exposed cohort demonstrated a median OS of 5.8 months (95% CI, 0.2–NR) and median PFS of 3.8 months (95% CI, 0.2–10.0). Penta-class defining drug classes were either combination GPRC5d directed regimens (n=12), combination BCMA directed regimens (n=2), BCMA directed monotherapy (n=1) or anti-CD38 combination therapy (n=1). Following penta-class progression, patients received either supportive care alone (n=8) or active myeloma treatment (n=8). With regards to subsequent active myeloma treatments; conventional regimens received included selinexor-based combinations (n=2), PI or IMiD based combination (n=2), and T-cell redirecting therapies included combination bispecific therapy (n=1), bispecific monotherapy (n=2) or tri-specific therapy (n=1). The 6-month PFS was 50% (95% CI, 19%–100%) for the conventional treatment group and 50% (95% CI, 19%–100%) for the T-cell redirecting therapy cohort.
Conclusion:
Despite advances in T-cell redirecting therapies, survival declines sharply with each successive class of exposure in relapsed multiple myeloma, reflecting substantial patient attrition in later lines. Sequential, piecemeal introduction of novel agents generates highly refractory clones associated with dismal outcomes. These contemporary Australian data provide updated real-world survival estimates for triple-, quad-class and penta-class exposed myeloma patients. The particularly poor survival of quadruple- and penta-class exposed patients highlights a major unmet need and underscores the importance of optimising treatment sequencing to achieve sustained early remissions prior to resistant clonal disease evolution.